SCHEMBL3534751

SCHEMBL3534751

CN1CCN(C(=O)N(C)c2ccc([N+](=O)[O-])c(N3CCCCC3)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.59
CSF1R P07333 1/20 0.52
MAPT P10636 11/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 2/20 0.47
NPSR1 Q6W5P4 3/20 0.47
MAPK1 P28482 2/20 0.47
GPR174 Q9BXC1 2/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5097941 0.83 ALDH1A1 (0.56) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL5104601 0.79 ALDH1A1 (0.62) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL4486069 0.76 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2L3MBTL1MAPK1
SCHEMBL31000456 0.74 ALDH1A1 (1.00) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL3536472 0.74 ALDH1A1 (1.00) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL3537670 0.74 ALDH1A1 (0.58) ALDH1A1CSF1RMAPTLMNASMN1; SMN2
SCHEMBL7515290 0.72 MAPT (0.58) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL20623078 0.72 ALDH1A1 (0.56) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL23928501 0.71 NPSR1 (0.74) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2
SCHEMBL14784645 0.70 ALDH1A1 (0.64) ALDH1A1MAPTLMNASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885CSF1R 34/4885MAPT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.